FIC EP2/EP4 dual antagonist
2024-07-19
- Program：FIC EP2/EP4 dual antagonist
- Indication: Antitumor
- Status：PCC
- Collaboration Opportunity: Equity financing, cooperative development, product transfer, etc.
- Highlights：
- EP2 and EP4 dual antagonists, potentially becoming dual-target FIC molecules in the prostaglandin pathway, effectively inhibit tumor growth and immune evasion, with no observed gastrointestinal or cardiovascular safety risks.
- Significant efficacy: It demonstrates superior efficacy compared to selective EP2 or EP4 antagonists and synergizes with anti-PD-1 in combating tumors.